Related Scientific Literature
- Diagnostic Testing for Severe Acute Respiratory Syndrome-Related Coronavirus-2: A Narrative Review
- Comparison of Commercially Available and Laboratory Developed Assays for in vitro Detection of SARS-CoV-2 in Clinical Laboratories
- COVID-19 Special Column: Principles Behind the Technology for Detecting SARS-CoV-2, the Cause of COVID-19
- Diagnostics for SARS-CoV-2 detection: A comprehensive review of the FDA-EUA COVID-19 testing landscape
- Detection of COVID-19: A review of the current literature and future perspectives
- Challenges in Laboratory Diagnosis of the Novel Coronavirus SARS-CoV-2
- Current and Perspective Diagnostic Techniques for COVID-19
- Molecular and Immunological Diagnostic Tests of COVID-19: Current Status and Challenges
- Comparison of four molecular in vitro diagnostic assays for the detection of sars-cov-2 in nasopharyngeal specimens
- Molecular, serological, and biochemical diagnosis and monitoring of COVID-19: IFCC taskforce evaluation of the latest evidence
- Current and Future Point-of-Care Tests for Emerging and New Respiratory Viruses and Future Perspectives
- SARS-CoV-2 detection in setting of viral swabs scarcity: Are MRSA swabs and viral swabs equivalent?
- Laboratory markers included in the Corona Score can identify false negative results on COVID-19 RT-PCR in the emergency room
- Rapid and sensitive detection of SARS-CoV-2 RNA using the Simplexaâ„¢ COVID-19 direct assay
- Molecular diagnosis of COVID-19 in different biologic matrix, their diagnostic validity and clinical relevance: A systematic review
- Assay Techniques and Test Development for COVID-19 Diagnosis.
- Clinical Evaluation and Utilization of Multiple Molecular In Vitro Diagnostic Assays for the Detection of SARS-CoV-2
- Comparison of Four Molecular In Vitro Diagnostic Assays for the Detection of SARS-CoV-2 in Nasopharyngeal Specimens
- A machine learning algorithm to increase COVID-19 inpatient diagnostic capacity
- Comparison of abbott id now, diasorin simplexa, and CDC fda emergency use authorization methods for the detection of sars-cov-2 from nasopharyngeal and nasal swabs from individuals diagnosed with covid-19
- Meta-analysis of the clinical performance of commercial SARS-CoV-2 nucleic acid, antigen and antibody tests up to 22 August 2020